Satellos Bioscience Inc., a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases, announced the appointment of Wildon Farwell, M.D., MPH, as chief medical officer. Dr. Farwell joins Satellos from Dyne Therapeutics, where he most recently served as CMO and medical advisor.
“We are thrilled to welcome Dr. Farwell as our CMO,” said Frank Gleeson, Satellos co-founder and CEO. “He brings deep expertise in global clinical development — particularly in neuromuscular and rare diseases — and a strong track record of successfully advancing novel therapies through regulatory approval. His experience will be invaluable as we move SAT-3247 into a global, randomized, placebo-controlled Phase 2 clinical trial in children living with DMD, with the goal of delivering a transformative treatment.”
Also Read: Scipher & Savant Bio to Build Top RA Clinico-Genomic Dataset
At Dyne, Dr. Farwell built the development organization, led the protocol development and regulatory submissions for their Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) programs, oversaw the conduct of multiple potentially registrational clinical studies, and contributed to several successful capital raises. Before joining Dyne, he spent a decade at Biogen in increasing leadership roles, including vice president of Late-Stage Clinical Development and global medical head of Neuromuscular Diseases. During his time at Biogen, Dr. Farwell led the development and lifecycle management of SPINRAZA®, the first approved treatment for spinal muscular atrophy. He also initiated late-stage development of QALSODY®, an investigational therapy for amyotrophic lateral sclerosis. Dr. Farwell also led biomarker development and pharmacovigilance for therapies across multiple indications. Prior to moving into industry, Dr. Farwell served as an assistant professor of medicine at Harvard Medical School and was a physician at Brigham and Women’s Hospital and the VA Boston Healthcare System. He earned his medical degree from the University of Missouri School of Medicine and holds a Master of Public Health in clinical effectiveness from the Harvard T.H. Chan School of Public Health.
“I’m honored to join Satellos at such a pivotal point in its growth,” said Dr. Farwell. “Throughout my career, I’ve been fortunate to lead the development of several therapies that have had profound impacts on the lives of specific populations of people with serious neuromuscular diseases. Now, working to advance SAT-3247 and support Satellos’ novel approach to muscle regeneration represents a natural and meaningful next chapter. I look forward to working with the team to drive clinical progress and bring forward a treatment that may have a profound impact across a broad population of people living with Duchenne and other serious muscle diseases.”
Source: Businesswire